SCHEDULE 13G/A: Suvretta Capital Management and Affiliates Disclose Significant Stake in Fulcrum Therapeutics

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen have filed an amended Schedule 13G, disclosing their beneficial ownership of 9.4% and 8.6% respectively, in Fulcrum Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership of Fulcrum Therapeutics, Inc. common stock.
• The filing indicates that Suvretta Capital Management, LLC and Aaron Cowen each beneficially own 5,067,394 shares, representing 9.4% of the class.
• Averill Master Fund, Ltd. beneficially owns 4,635,481 shares, representing 8.6% of the class.
• All reporting persons share voting and dispositive power over their reported shares.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of Fulcrum Therapeutics, Inc., except for activities solely related to a nomination under Rule 14a-11.
• Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC.
• All reported securities are directly owned by advisory clients of Suvretta Capital Management, LLC, with Averill Master Fund, Ltd. being the only other client known to beneficially own more than 5%.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational or financial news.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant beneficial ownership by institutional investors and their affiliates, common in the financial industry to provide transparency on large holdings in publicly traded companies. It reflects an investment position rather than operational or strategic changes within Fulcrum Therapeutics, Inc.

Related Party Transactions

• Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC.
• Averill Master Fund, Ltd. is an advisory client of Suvretta Capital Management, LLC and beneficially owns more than 5% of the Common Stock.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
• Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership exceeding 5%.

Key Dates

Keywords

Fulcrum Therapeutics, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Management